Welcome to our dedicated page for Harte-Hanks news (Ticker: HHS), a resource for investors and traders seeking the latest updates and insights on Harte-Hanks stock.
Harte Hanks, Inc. reports news as a customer experience company serving clients through Revenue Solutions, Customer Care, and Fulfillment & Logistics Services. Company updates commonly cover quarterly and annual results, revenue trends by segment, EBITDA and adjusted EBITDA measures, cost controls, customer contract transitions, and operating initiatives such as Project Elevate.
Recurring developments also include customer care partnerships, data-driven marketing assets, healthcare marketing capabilities, leadership changes, and financing actions such as amendments to its asset-based revolving credit facility. Its Fulfillment & Logistics Services business includes printing, lettershop, mail optimization, logistics, transportation optimization, monitoring, and tracking for traditional and specialized mailings.
Harte Hanks (NYSE: HHS) has been chosen by Flagship Biosciences to implement a strategic marketing campaign aimed at enhancing customer acquisition. This initiative will encompass a targeted, multi-channel approach, integrating email, digital advertising, and content creation to engage critical decision-makers in the biotechnology sector. The campaign's objective is to showcase Flagship's capabilities in accelerating drug development and improving patient outcomes, leveraging Harte Hanks' expertise in behavioral marketing.
Harte Hanks (NYSE: HHS) announced the upcoming release of its financial results for Q1 2020, which ended on March 31, 2020. The results will be made public on May 14, 2020, after market close. A conference call to discuss these results is scheduled for the same day at 4:30 p.m. ET. Interested parties can join the call by dialing (877) 300-8521 or (412) 317-6026, using conference ID 10144089. The call will also be available via live webcast on the company's website, along with a replay for 90 days following the event.